

ALEXION PHARMACEUTICALS INC

Form 4

December 15, 2015

FORM 4**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
NORBY R DOUGLAS

2. Issuer Name **and** Ticker or Trading
Symbol
ALEXION PHARMACEUTICALS
INC [ALXN]

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

(Last) (First) (Middle)
C/O ALEXION
PHARMACEUTICALS, 352
KNOTTER DRIVE

3. Date of Earliest Transaction
(Month/Day/Year)
12/11/2015

☒ Director ☐ 10% Owner
☐ Officer (give title below) ☐ Other (specify below)

(Street)
CHESHIRE, CT 06410

4. If Amendment, Date Original
Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check
Applicable Line)
☒ Form filed by One Reporting Person
☐ Form filed by More than One Reporting
Person

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership Indirect Beneficial Ownership (Instr. 4)
Common Stock, par value \$.0001 per share	12/11/2015		A	13,000	A \$ 18.01 45,481	D	
Common Stock, par value \$.0001 per share	12/11/2015		A	12,276	A \$ 16.83 57,757	D	

Edgar Filing: ALEXION PHARMACEUTICALS INC - Form 4

Common Stock, par value \$.0001 per share	12/11/2015	A	7,932	A	\$ 26.64	65,689	D
Common Stock, par value \$.0001 per share	12/11/2015	A	5,572	A	\$ 49.43	71,261	D
Common Stock, par value \$.0001 per share	12/11/2015	A	3,237	A	\$ 85.75	74,498	D
Common Stock, par value \$.0001 per share	12/11/2015	A	3,425	A	\$ 96.35	77,923	D
Common Stock, par value \$.0001 per share	12/11/2015	S	34	D	\$ <u>(1)</u> 186.97	77,889	D
Common Stock, par value \$.0001 per share	12/11/2015	S	35,575	D	\$ <u>(2)</u> 187.57	42,314	D
Common Stock, par value \$.0001 per share	12/11/2015	S	9,833	D	\$ <u>(3)</u> 188.24	32,481	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security	2. Conversion or Exercise	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any	4. Transaction Code	5. Number of	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying	8. Price of Derivative Security	9. Number of Derivative Securities
---------------------------------------	------------------------------	---	---	------------------------	-----------------	--	---	---------------------------------------	--

Reporting Owner Name / Address

Director	10% Owner	Officer	Other
----------	-----------	---------	-------

Signatures

12/15/2015

Date _____

Explanation of Responses:

- Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.